ClinicalTrials.gg
RecruitingNCT07130773Updated Mar 19, 2026

Comparative Intra-procedural Evaluation of Farapulse and FARAWAVE Nav Catheters

An interventional study of Second-generation FARAWAVE Nav catheter without the use of pre-ablation CT and FARAPULSE with pre-ablation CT in Atrial Fibrillation (AF), Atrial Fibrillation Ablation and Pulsed Field Ablation, sponsored by Cardiocentro Ticino. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Cardiocentro Ticino · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 117 studies in Atrial Fibrillation with a site in Switzerland — 23 open to participants now, 33 under way, 1 of them phase 3. Atrial Fibrillation · Switzerland.

Planned enrollment
62nd of 70
58 · median 409
Started
2025
with 4 others
No phase
31 of 117
7 open now
Primary completion
2026-08
later than 7 of 32 live
Registered
108th of 117
by date

Among the 117 studies in Atrial Fibrillation with a site in Switzerland, this one is the 62nd largest by planned enrollment of the 70 interventional ones that give a count, is one of 5 that started in 2025, is one of 31 with no phase, reaches primary completion later than 7 of the 32 other live ones, and was the 108th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

23 of the 117 studies in Atrial Fibrillation with a site in Switzerland are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 117 studies in Atrial Fibrillation with a site in Switzerland, or all of them as a file.
02

Study summary

The FARAPULSE PFA catheter (Boston Scientific), a first-generation Pulsed Field Ablation (PFA) tool, has demonstrated good performance in isolating pulmonary veins (PV). Several centers, including ours, utilize pre-procedural computer tomography (CT) to evaluate individual pulmonary vein anatomy and optimize ablation planning. However, these imaging modalities are costly. Additionally, CT imaging exposes patients to radiation, and introduce significant logistical challenges to the procedural workflow.

The FARAWAVE Nav PFA catheter, a second-generation device, integrates magnetic navigation capabilities with detailed mapping and PFA therapy into a single tool. This system leverages the FARAVIEW Software Module, offering tailored mapping solutions visualized on the FARAPULSE PFA system, including the creation of voltage and activation maps.

These features address the limitations of the first-generation FARAPULSE catheter and have the potential to improve procedural accuracy and the durability of pulmonary vein isolation. Moreover, they may obviate the need for pre-procedural CT, thereby reducing costs and minimizing patient radiation exposure.

Our study evaluates whether the FARAWAVE Nav catheter, used without pre-ablation CT, allows for a reduction in fluoroscopy time and overall patient radiation exposure compared to the conventional workflow with the FARAPULSE catheter. Furthermore, we will assess procedural time, costs, number of PFA applications, and AF recurrence-free survival

Read the detailed description

The FARAPULSE PFA catheter (Boston Scientific), a first-generation Pulsed Field Ablation (PFA) tool, has demonstrated good performance in isolating pulmonary veins (PV) as standard of care for atrial fibrillation (AF) ablation. Several centers, including ours, utilize pre-procedural CT or cardiac magnetic resonance (CMR) imaging to evaluate individual pulmonary vein anatomy and optimize ablation planning. However, these imaging modalities are costly. Additionally, CT imaging exposes patients to radiation, and both CT and CMR add significant logistical challenges to the procedural workflow.

The FARAWAVE Nav PFA catheter, a second-generation device, integrates magnetic navigation capabilities with detailed mapping and PFA therapy into a single device. This system leverages the FARAVIEW Software Module, offering tailored mapping solutions visualized on the FARAPULSE PFA System, including the creation of voltage and activation maps. Key technical enhancements of the FARAWAVE Nav PFA catheter include: Field Tag Technology: Field tagging estimates field volume and indicates energy delivery locations. Tags confirm overlap between applications, ensuring comprehensive PV isolation. Voltage/Activation Maps: Mapping data enhances procedure precision, allowing visualization of electrical activation and PV anatomy without reliance on pre-ablation CT imaging. These features address the limitations of the first-generation FARAPULSE catheter and have the potential to enhance procedural accuracy and the durability of pulmonary vein isolation. Moreover, they may eliminate the need for pre-procedural CT or CMR, thereby reducing costs and minimizing patient exposure to radiation.

Our center, like several others, has used the first-generation catheter in routine clinical practice for over a year. More recently, we have also started using the second-generation catheter as part of standard clinical care. Currently, the two devices are used interchangeably, depending on logistical availability, particularly the presence of specialized technicians from Boston Scientific, who are required for the proper operation of the second-generation catheter.

Our study evaluates whether the FARAWAVE Nav catheter, without pre-ablation CT, allows to reduce fluoroscopy time and total patient radiation load as compared to conventional workflow with FARAPULSE catheter. Furthermore, procedural time, costs, number of PFA applications and AF recurrence free survival will be assessed.

Inclusion Criteria

  • Atrial fibrillation (AF) documented on a 12-lead ECG, Holter monitor, or implantable cardiac device.
  • Candidate for ablation according to current atrial fibrillation guidelines.
  • Age ≥18 years at the time of informed consent.
  • Signed informed consent obtained.

Exclusion Criteria

  • Previous left atrial ablation or left atrial surgery.
  • Presence of intracardiac thrombus.
  • Persistent atrial fibrillation lasting >3 years.
  • Severe mitral regurgitation or moderate-to-severe mitral stenosis.
  • Pregnancy (all women under 50 years undergo an HCG blood test prior to inclusion to exclude pregnancy).

Primary Endpoint

1. Fluoroscopy Time (measured in minutes)

Secondary Endpoints 2.1 Total Patient Radiation Load 2.2 Procedural Costs 2.3 Procedure Time 2.4 Left Atrial Dwelling Time 2.5 Fluoroscopy Time After Transseptal Puncture 2.6 Number of PFA Applications 2.7 AF Recurrence-Free Survival 2.8 AF Burden (in Patients with implantable loop recorder) 2.9 AF Burden (All Patients)

Randomization: 58 Patients will be randomized 1:1 to:

  1. FARAPULSE + pre-ablation CT (Control Group, n=29).
  2. FARAWAVE Nav without pre-ablation CT (Intervention Group, n=29). Randomization will be performed using stratified allocation based on Atrial Fibrillation pattern (paroxysmal vs. persistent AF) in a 1:1 fashion.

Intraprocedural fluoroscopy time will be collected at the time of AF ablation procedure.

To determine the required sample size for this study, we performed calculations based on previous studies, the expected fluoroscopy time are:

Control Group: Mean fluoroscopy time = 12 minutes, SD = 8 minutes [doi.org/10.1161/CIRCULATIONAHA.123.064959] Intervention Group: Mean fluoroscopy time = 7 minutes, SD = 7 minutes [doi:10.1161/CIRCEP.122.011780] Given these assumptions, that correspond to an effect size (Cohen'd) of 0.80, a power of 80% and a 2-sided alpha of 5%, we will need to enrol 52 patients (26 per group). To ensure the study remains adequately powered despite potential dropouts, protocol deviations, or missing data, an additional 10% buffer may be considered, bringing the total recommended enrolment to 58 patients per group. Calculations have been performed using the Stata software (release 18.5, StataCorp, College Station, TX, USA).

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Atrial Fibrillation Ablation
  • Pulsed Field Ablation

Browse trials for

Keywords

  • pulsed filed ablation
  • atrial fibrillation
  • ablation
  • pulmonary vein isolation
  • electroanatomical map
  • ionizing radiation
  • farapulse
  • farawave nav
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Atrial fibrillation (AF) documented on a 12-lead , Holter monitor, or implantable cardiac device.
  • Candidate for ablation according to current atrial fibrillation guidelines.
  • Age ≥18 years at the time of .
  • Signed informed consent obtained

Exclusion criteria

Exclusion Criteria:

  • Previous left atrial ablation or left atrial surgery.
  • Presence of intracardiac thrombus.
  • Persistent atrial fibrillation lasting >3 years.
  • Severe mitral regurgitation or moderate-to-severe mitral stenosis.
  • Pregnancy (all women under 50 years undergo an HCG blood test prior to inclusion to exclude pregnancy).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Intervention

    FARAWAVE Nav without pre-ablation CT

    Device: Second-generation FARAWAVE Nav catheter without the use of pre-ablation CT

  • Active comparator
    Control

    FARAPULSE with pre-ablation CT

    Device: FARAPULSE with pre-ablation CT

Interventions

  • DeviceSecond-generation FARAWAVE Nav catheter without the use of pre-ablation CT

    FARAWAVE Nav without pre-ablation CT (Intervention Group, n = 29) Description of the investigation-specific intervention: Participants in the intervention group will undergo pulmonary vein isolation (PVI) using the second-generation FARAWAVE Nav pulsed field ablation (PFA) catheter without the use of pre-ablation CT imaging. The FARAWAVE Nav catheter integrates magnetic navigation and electroanatomical mapping capabilities, allowing real-time visualization of left atrial anatomy and electrical signals. Energy delivery is based on non-thermal pulsed electric fields (irreversible electroporation), specifically targeting myocardial tissue while sparing surrounding structures.

  • DeviceFARAPULSE with pre-ablation CT

    FARAPULSE with pre-ablation CT (Control Group, n = 29) Description of the investigation-specific intervention: Participants in the control group will undergo pulmonary vein isolation (PVI) using the first-generation FARAPULSE pulsed field ablation (PFA) catheter. All patients in this group will undergo pre-procedural cardiac CT imaging to evaluate pulmonary vein anatomy and assist in procedural planning. The FARAPULSE catheter delivers non-thermal pulsed electric fields for selective myocardial ablation, aiming to achieve electrical isolation of the pulmonary veins.

06

What researchers measure

Primary outcomes

  1. Fluoroscopy time

    The primary outcome of this investigation is fluoroscopy time, measured in minutes during the pulmonary vein isolation procedure. This outcome was chosen because it directly reflects the amount of radiation exposure experienced by the patient and is a critical measure of procedural efficiency and safety. For patients undergoing PVI plus additional left or right atrial ablations (planned or unplanned) the fluoroscopy time will be counted until the last application of the PVI. Fluoroscopic times will be compared between groups using the unpaired Student t test. The mean difference and 95%CI will be computed. In case of skewness, data will be log-transformed before entering the test. In this the mean difference on the log scale and the ratio on the original scale will be presented, both with 95%CI.

    Time frame: immediately after the procedure

Secondary outcomes

  1. Total Patient Radiation Load

    Total patient radiation load (cGy·cm²): to assess overall radiation exposure, including both imaging and intra-procedural sources. In case a patient randomized to the control group has already undergone a cardiac CT scan for another clinical reason in the past, the scan will not be repeated for ethical reasons. However, for the purpose of radiation dose calculation, the average radiation dose of a cardiac CT scan will be added as if the scan had been performed. Conversely, if a patient in the intervention group has previously undergone a cardiac CT scan, the operator will not review this scan prior to the procedure, and the corresponding radiation dose will not be included in the calculation. Analysis: same as the primary endpoint

    Time frame: immediately after the procedure

  2. Procedure Time

    Procedure time (minutes): to evaluate procedural efficiency from catheter insertion to removal. For patients undergoing PVI plus additional left or right atrial ablations (planned or unplanned) the procedure time will be counted until the last application of the PVI. Analysis: same as the primary endpoint

    Time frame: immediately after the procedure

  3. Left Atrial Dwelling Time

    Left atrial dwelling time (minutes): to assess the duration of catheter presence in the left atrium, which is associated with thromboembolic and procedural risks. Analysis: same as the primary endpoint.

    Time frame: immediately after the procedure

  4. Fluoroscopy Time After Transseptal Puncture

    Fluoroscopy time after transseptal puncture (minutes): to determine radiation exposure specifically during the left atrial portion of the procedure.

    Time frame: immediately after the procedure

  5. Number of PFA Applications

    Number of PFA applications: to evaluate treatment burden and procedural complexity.

    Time frame: immediately after the procedure

  6. AF Recurrence-Free Survival

    AF Recurrence-Free Survival: Freedom from AF, atrial flutter, or atrial tachycardia lasting \>30 seconds, documented by ILR, over a 12-month follow-up, after two months of blanking period. Kaplan Meier event-free curves will be presented for each group and compared with the logrank test. Hazard ratios (HR) and 95%CI will be derived from a Cox model. Follow-up will start after the two months blanking period. Patients who die without atrial arrhythmia recurrence will be censored at the time of death

    Time frame: up to 6 months

  7. AF Burden

    AF Burden: Proportion of time in AF, as assessed by the ILR over 6 months or 7 days Holter monitor. The same analysis as for the primary endpoint will be used.

    Time frame: up to 6 months

Other outcomes

  1. Procedural Costs

    Procedural costs: Pre-procedural imaging and procedural costs \[Cost of CT scan, FARAPULSE Catheter, FARAVEIW Catheter.\] The same analysis as for the primary endpoint will be used. In addition the ICER - incremental cost-effectiveness ratio - will be computes as the ratio of the difference in costs over the difference in effect as measures for the primary endpoint

    Time frame: immediately after the procedure

07

Study locations

1 of 1 sites recruiting
  • Cardiocentro Ticino - Ente Ospedaliero Cantonale
    Lugano, Canton Ticino 6900, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Aug 2026, 9 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 9 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 19, 2025
StartActual
Nov 10, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Dec 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07130773
Lead sponsor
Cardiocentro Ticino
Responsible party
Marco Bergonti (MD PhD, Cardiocentro Ticino) — Principal investigator
First posted
Aug 19, 2025
Start date
Nov 10, 2025
Primary completion
Aug 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 19, 2026

Study contacts

Marco Bergonti, MD PhD
Contact
bergmar21@gmail.com
+41 (0) 91 811 51 11

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion